Xilio Therapeutics Files 8-K on Shareholder Vote
Ticker: XLO · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1840233
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Xilio held a shareholder vote on June 10th, filing the details today.
AI Summary
Xilio Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders on June 10, 2025. The filing details the company's principal executive offices located at 828 Winter Street, Suite 300, Waltham, Massachusetts, 02451.
Why It Matters
This filing indicates that Xilio Therapeutics held a shareholder vote, which is a standard corporate governance event but can sometimes precede significant strategic decisions or changes.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure regarding a shareholder vote and does not contain information about significant financial events or strategic shifts.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
- June 12, 2025 (date) — Date of report
- 828 Winter Street, Suite 300 (location) — Principal Executive Offices
- Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What was the specific purpose of the shareholder vote reported in this 8-K?
The filing states it is reporting on 'Submission of Matters to a Vote of Security Holders' but does not specify the exact matters voted upon in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 10, 2025.
What is Xilio Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts, 02451.
What is the SEC file number for Xilio Therapeutics, Inc.?
The SEC file number is 001-40925.
What is the IRS Employer Identification Number (EIN) for Xilio Therapeutics, Inc.?
The IRS Employer Identification Number is 85-1623397.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding Xilio Therapeutics, Inc. (XLO).